Immediate Impact

57 standout
Sub-graph 1 of 24

Citing Papers

Pre-metastatic niche: formation, characteristics and therapeutic implication
2024 Standout
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
2024 Standout
2 intermediate papers

Works of Alexandra Savell being referenced

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
2019
A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients
2017

Author Peers

Author Last Decade Papers Cites
Alexandra Savell 142 71 72 111 96 15 237
H. Yesid Estupiñán 193 63 84 130 56 18 291
Fernando Solano 98 53 59 118 62 16 259
Giulia Poretti 112 68 58 143 100 11 280
Laura Stampleman 112 104 29 85 94 17 228
Efstathios Koulieris 102 136 45 85 101 22 252
Iryna Kryachok 125 35 69 121 64 19 190
Grégory Lazarian 174 39 70 135 54 16 201
Shayne Atkinson 207 46 68 197 99 11 283
Jean Cheung 102 30 39 92 62 15 196
Gandhi Damaj 78 39 173 78 79 14 280

All Works

Loading papers...

Rankless by CCL
2026